Xponance’s iBio IBIO Stock Holding History

Xponance’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-20	Closed	-$4K	–	1207
2022 Q1	$4K	Sell	20 -1	-5%	-$209	﹤0.01%	1167
2021 Q4	$6K	Buy	21 +1	+5%	+$381	﹤0.01%	1171
2021 Q3	$11K	Hold	20	–	–	﹤0.01%	1170
2021 Q2	$15K	Buy	+20	New	+$14.6K	﹤0.01%	1246

Other funds holding IBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Xponance's IBIO Position: Q2 2022 in Review

Xponance sold out of iBio (IBIO) in Q2 2022, closing a stake of 20 shares — an estimated $4K sold.

Xponance first reported a position in IBIO in Q2 2021 and held it in 4 quarters. The position peaked at $15K in Q2 2021. 53 funds tracked by Wall St. Rank hold IBIO as of Q2 2022.

Xponance reported no remaining iBio position as of Q2 2022 after selling out during the quarter.
Xponance sold 20 iBio shares in Q2 2022, an estimated $4K.
Xponance first reported a position in iBio in Q2 2021 and held it in 4 quarters.
Xponance's iBio position peaked at $15K in Q2 2021.
53 funds tracked by Wall St. Rank held iBio as of Q2 2022.

Based on Xponance's 13F filing for Q2 2022, filed 2 Aug 2022.